367 related articles for article (PubMed ID: 26108897)
1. Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines.
Marcus RK; Geurts JL; Grzybowski JA; Turaga KK; Clark Gamblin T; Strong KA; Johnston FM
Fam Cancer; 2015 Dec; 14(4):641-9. PubMed ID: 26108897
[TBL] [Abstract][Full Text] [Related]
2. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
[TBL] [Abstract][Full Text] [Related]
3. Acceptability of, and Information Needs Regarding, Next-Generation Sequencing in People Tested for Hereditary Cancer: A Qualitative Study.
Meiser B; Storey B; Quinn V; Rahman B; Andrews L
J Genet Couns; 2016 Apr; 25(2):218-27. PubMed ID: 26259529
[TBL] [Abstract][Full Text] [Related]
4. Consensus document on the implementation of next generation sequencing in the genetic diagnosis of hereditary cancer.
Soto JL; Blanco I; Díez O; García Planells J; Lorda I; Matthijs G; Robledo M; Souche E; Lázaro C
Med Clin (Barc); 2018 Jul; 151(2):80.e1-80.e10. PubMed ID: 29439875
[TBL] [Abstract][Full Text] [Related]
5. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
DiNardo CD; Routbort MJ; Bannon SA; Benton CB; Takahashi K; Kornblau SM; Luthra R; Kanagal-Shamanna R; Medeiros LJ; Garcia-Manero G; M Kantarjian H; Futreal PA; Meric-Bernstam F; Patel KP
Cancer; 2018 Jul; 124(13):2704-2713. PubMed ID: 29682723
[TBL] [Abstract][Full Text] [Related]
6. Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.
Kamps R; Brandão RD; Bosch BJ; Paulussen AD; Xanthoulea S; Blok MJ; Romano A
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146134
[TBL] [Abstract][Full Text] [Related]
7. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.
Soukupova J; Zemankova P; Lhotova K; Janatova M; Borecka M; Stolarova L; Lhota F; Foretova L; Machackova E; Stranecky V; Tavandzis S; Kleiblova P; Vocka M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z
PLoS One; 2018; 13(4):e0195761. PubMed ID: 29649263
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.
Castellanos E; Gel B; Rosas I; Tornero E; Santín S; Pluvinet R; Velasco J; Sumoy L; Del Valle J; Perucho M; Blanco I; Navarro M; Brunet J; Pineda M; Feliubadaló L; Capellá G; Lázaro C; Serra E
Sci Rep; 2017 Jan; 7():39348. PubMed ID: 28051113
[TBL] [Abstract][Full Text] [Related]
9. Genetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testing.
Boland PM; Ruth K; Matro JM; Rainey KL; Fang CY; Wong YN; Daly MB; Hall MJ
Clin Genet; 2015 Dec; 88(6):565-72. PubMed ID: 25523111
[TBL] [Abstract][Full Text] [Related]
10. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
11. The impact of hereditary cancer gene panels on clinical care and lessons learned.
Okur V; Chung WK
Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 29162654
[TBL] [Abstract][Full Text] [Related]
12. Gene panel testing for inherited cancer risk.
Hall MJ; Forman AD; Pilarski R; Wiesner G; Giri VN
J Natl Compr Canc Netw; 2014 Sep; 12(9):1339-46. PubMed ID: 25190699
[TBL] [Abstract][Full Text] [Related]
13. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
[TBL] [Abstract][Full Text] [Related]
14. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of laboratory perspectives on hereditary cancer panels.
Stoll J; Weissman SM; Hook N; Selkirk C; Johnson AK; Newlin A; Vogel Postula KJ
Fam Cancer; 2016 Oct; 15(4):689-96. PubMed ID: 26869169
[TBL] [Abstract][Full Text] [Related]
16. Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer.
Tafe LJ
J Mol Diagn; 2015 Sep; 17(5):472-82. PubMed ID: 26162329
[TBL] [Abstract][Full Text] [Related]
17. Genetic Testing: Challenges and Changes in Testing for Hereditary Cancer Syndromes.
King E; Mahon SM
Clin J Oncol Nurs; 2017 Oct; 21(5):589-598. PubMed ID: 28945723
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.
Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW
J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).
DiNardo CD; Bannon SA; Routbort M; Franklin A; Mork M; Armanios M; Mace EM; Orange JS; Jeff-Eke M; Churpek JE; Takahashi K; Jorgensen JL; Garcia-Manero G; Kornblau S; Bertuch A; Cheung H; Bhalla K; Futreal A; Godley LA; Patel KP
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):417-428.e2. PubMed ID: 27210295
[TBL] [Abstract][Full Text] [Related]
20. Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next-Generation Sequencing Panel Testing.
Mu W; Lu HM; Chen J; Li S; Elliott AM
J Mol Diagn; 2016 Nov; 18(6):923-932. PubMed ID: 27720647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
